QBTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
QBTS is not a good buy right now for an impatient trader. The stock is in a short-term downswing (bearish momentum and price sitting just below a key support), and there are no Intellectia proprietary buy signals to justify rushing an entry today. Despite strong long-term thematic upside (quantum contracts + very bullish Street targets), the current setup favors waiting for stabilization/reclaim of support (22.60) and/or a move back above the pivot (25.78) before buying.
Price/Trend: QBTS is down -4.22% to ~22.27, trading below S1 (22.608) and closer to S2 (20.646), which signals the market is pressuring support rather than bouncing cleanly. Momentum: MACD histogram is -0.67 and expanding negatively, indicating strengthening bearish momentum. RSI: RSI_6 at 25.29 is effectively oversold, which can support a reflex bounce, but oversold can persist when MACD is still deteriorating. Moving averages: Converging MAs suggest a transition zone, but with current momentum/price location the near-term bias remains cautious. Levels: Immediate support zone is 22.60 then 20.65; overhead resistance is 25.78 (pivot), then 28.96.
Intellectia Proprietary Trading Signals
News-driven catalyst: Announcement/coverage around $30M in contracts/agreements (Jan 27–
supports the commercialization narrative and can trigger momentum rallies.
Industry tailwinds: Continued investor focus on quantum computing and large TAM projections.
Analyst momentum: Multiple firms initiated or raised targets recently with consistent Buy/Outperform/Overweight views.
Gross margin improvement: 2025/Q3 gross margin rose to ~71.38% (+27.97% YoY), supporting operating leverage potential if revenue scales.
Technical damage: Price is below a key support (22.608) with a negatively expanding MACD—risk of continuation toward ~20.65.
Volatility/regime risk: Quantum names have been extremely volatile; near-term moves can be sharp in both directions, making timing critical (especially for impatient entries).
Profitability still far: Latest quarter shows very large losses (net income -$139.99M), which can pressure sentiment on any risk-off tape.
No supportive proprietary timing signal: Absence of AI Stock Picker / SwingMax entry reduces confidence in an immediate “buy now” timing call.
Latest quarter provided: 2025/Q3.
Trend: Analyst sentiment is overwhelmingly bullish and getting more bullish, with multiple recent initiations (Outperform/Buy/Overweight) and repeated price-target raises. Recent changes: Canaccord and Rosenblatt both raised targets to $43 in January 2026; earlier initiations/targets clustered in the $35–$46 range (Wedbush $35; Jefferies $45; Mizuho $46; Evercore $44; Cantor $40; Benchmark $35). Wall Street pros: First-mover commercialization narrative, annealing leadership, improving ecosystem/tailwinds, contract wins, and margin improvement. Wall Street cons (implicit): Early-stage commercialization and ongoing heavy losses; execution risk remains high. Holdings/Influential trading: Hedge funds and insiders are reported as Neutral (no significant trends). Congress trading: No recent congress trading data available in the last 90 days.
